Navigation Links
ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
Date:8/11/2009

in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to (i) Anadys' belief that ANA773 holds promise as a potential replacement for injectable interferon products in HCV therapy; (ii) Anadys' ability to seek and obtain partnership opportunities to further the development of ANA773; (iii) the ability to create well-tolerated, all oral combination regimens to treat hepatitis C; (iv) the potential to further improve response by combining ANA773 with other agents, including ribavirin; and (v) the potential for alternative dosing schedules to further improve pharmacological response to TLR7 activation. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA773 will not have unforeseen safety issues or will have favorable results in future clinical studies. Furthermore, Anadys cannot provide any assurances that it will be able to obtain a partnership around ANA773 or that the development of the program will be continued. In addition, Anadys' results may be affected by risks related to competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into collaborations around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its product candidates, regulatory developments involving its product candidates and its ability to obtain additional funding to support
'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class
2. Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
3. Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis
4. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
5. Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
6. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
7. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
8. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
9. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
10. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
11. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... KENNESAW, Ga. and RALEIGH, ... Clinical Trial Marketing Communications, LLC (CTMC), and Integrated ... in patient recruitment and retention for clinical trials ... called Integrated Clinical Trial Marketing Services (i-CTMS). i-CTMS ... and retention services to pharmaceutical, biotechnology and medical ...
(Date:12/15/2014)... 2014 Registreer nu via  http://bit.ly/ag8Sypm14de ... 20. Februar sind alle akkreditierten pharmazeutischen Patientenversorgungsakten-Firmen ... PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, der Aegate ... neue profitablen Unternehmensdienstleistungen, die für Apotheken und ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... of the "Electrocardiogram (ECG) Devices - Global Trends, ... http://photos.prnewswire.com/prnh/20130307/600769 ... US$330 million by 2016. The North America ... global market share while Europe ...
Breaking Medicine Technology:Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
(Date:12/20/2014)... 2014 Developers of FCPX ... new plugin for Final Cut Pro X entitled TranSlice ... 5 allows users to create hand drawn text animations ... Austin, CEO of Pixel Film Studios. “TranSlice Volume 5 ... maintaining an easy to use interface.” , TranSlice Volume ...
(Date:12/20/2014)... 2014 Today, Balfleet.com, one of the ... Sale, offering 50%-70% off on its Mother of ... The mother of the bride dresses from Balfleet.com feature ... 24/7 accessible and takes pride in providing high quality ... are offering great discounts on our mother of the ...
(Date:12/19/2014)... Sarasota, Florida (PRWEB) December 19, 2014 Sub ... Bank to sponsor a blood drive Sunday the 28th from ... Clark Road & Sawyer Road in Sarasota, FL. , Inquiries ... special thank you for participating in the donating process, Sub ... a free flash frozen, custom ice cream. , About Sub ...
(Date:12/19/2014)... 19, 2014 SuperCloset raises the bar ... SuperCloset continues to offer indoor growers the most efficient ... the new SuperClone Rooms with the award winning ... indoor hydroponic grow room setup. , The SuperClone Room ... SuperPonic SuperCloner 50 . The SuperClone ...
(Date:12/19/2014)... 2014 The Medspa at Hendrick in ... from respected cosmetic brand Juvéderm. Voluma XC treats volume ... The Medspa at Hendrick is pleased to be able ... technology to its clients. , Voluma is the first ... to treat the mid-face and cheek area. This non-invasive ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2
... 2010 - Think back to your last fight with someone you ... behave? Conflict with a loved one often leaves a person feeling ... scenarios have become soap opera clichs. After an argument, one ... local bar to drown their sorrows in alcohol. These dramas ...
... insulin to treat diabetes far outweigh the risks, but ... Journal of Clinical Practice, suggests that commonly used diabetes ... to their influence on cancer risk. Cancer expert ... up with diabetes expert Professor David Russell-Jones from The ...
... Fla. For his work contributing to a potential new ... (MJFF) for Parkinson,s Research has awarded a $500,000 grant to ... The researcher, Matthew Farrer, Ph.D., studies how a gene, known ... also how it can go awry when mutated. Dr. Farrer ...
... ... Malaria on April 24, 2010. , ... Washington, DC (Vocus) March 2, 2010 -- The United Nations Foundation and its ... partnered with Bobby Bailey to produce a new documentary on the deadliest plague known to ...
... ... 97.5 The Fanatic team up to promote men’s prostate health with a fun, free program. ... Abington, PA (Vocus) March 2, 2010 -- ... from Abington Memorial Hospital for a free program just for men: Knowing the Score: ...
... Junk food intake is up, and many kids have few places ... -- New research finds that the prevalence of obesity has grown ... kids are being especially hard hit. , And another study in ... snacking on potato chips, candy and other fattening foods an average ...
Cached Medicine News:Health News:Don't make that face at me! 2Health News:Experts call for further research into the relationship between insulin therapy and cancer 2Health News:Experts call for further research into the relationship between insulin therapy and cancer 3Health News:Michael J. Fox Foundation awards Mayo Clinic researcher grant to advance Parkinson’s research 2Health News:Invisible Children's Bobby Bailey Premiers a New Documentary on Malaria 2Health News:Invisible Children's Bobby Bailey Premiers a New Documentary on Malaria 3Health News:Knowing the Score: The Key to Prostate Health 2Health News:Child Obesity Rates Going Up 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: